Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide

U.S. Customs and Border Protection told Reuters the agency intercepted over 690 shipments - totaling more than 31,000 units - of illicit GLP-1 drugs during fiscal year 2025. In the month of July, those figures more than doubled, with over 1,400 seizures and nearly 90,000 vials intercepted.

"Every single time that someone takes one of these, they're exposing themselves to a huge amount of risk," said Lilly's Dr. Max Denning, Associate Vice President, Therapeutic Area Lead – Global Patient Safety Cardiometabolic Health.

The six lawsuits were filed against Aesthetic Envy Cosmetic Centers, Astra LLC, Legendary Peptides, Striker Pharmacy, Texas Peptides and Lone Star Peptide Co, according to Lilly.